SUI treatment reaches "new frontier” with regenerative medicine and stem cell–based therapiesJanuary 19th 2022
In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Melissa R. Kaufman, MD, PhD, FACS, discusses the innovative use of stem cell–derived treatments in urologic conditions such as stress urinary incontinence.
Dr. Haag-Molkenteller on implications of vibegron phase 3 EMPOWUR extension studyJanuary 14th 2022
"This analysis of this publication confirms the link between efficacy and the patient perception, and that the results are actually meaningful to the patients as well," says Cornelia Haag-Molkenteller, MD, PhD.
Study finds significant association between age and OABJanuary 11th 2022
This study underscores how common urinary incontinence is in women, with nearly 1 in 5 Japanese women reporting urinary incontinence related to OAB or SUI in the last month,” said Stephanie Faubion, MD, MBA, medical director of the North American Menopause Society.
OAB risk varies in patients taking cholinesterase inhibitors for dementiaJanuary 11th 2022
“Using a national cohort of older adults with dementia, we…found that donepezil was associated with a 13% increased risk of OAB compared to rivastigmine,” says study author Rajender R. Aparasu, PhD
Urinary incontinence linked to increased risk of falling in older adultsDecember 17th 2021
“Falls are the leading cause of accidental death in seniors, and many people don’t know that having bladder control problems makes you about twice as likely to fall over,” said William Gibson, MBChB, MRCP, PhD.
Pivotal trial of neuromodulation device for urge urinary incontinence completes enrollmentNovember 18th 2021
The RENOVA iStim tibial neuromodulation system is a wireless peripheral neurostimulator device that a clinician implants in the patient’s ankle with the patient under local anesthesia.
Dr. Ginsberg urges clinicians to consider onabotulinumtoxinA for OAB and urinary incontinenceNovember 17th 2021
“Men do well and they don't have a really high risk of outcomes that we don't want them to have and that patients don't want to have, which is really the need to catheterize,” says David A. Ginsberg, MD.
Study finds vibegron has no adverse ambulatory effects in patients with OABNovember 5th 2021
In a recent study, Michael A. Weber, MD, and co-authors assessed the blood pressure and heart rate profiles of the beta 3 adrenergic receptor agonist vibegron in treating patients with OAB.
Expert discusses studies of Optilume drug-coated balloon for urethral stricturesNovember 2nd 2021
“What our studies were looking at was a novel device that could potentially help bridge the gap between [endoscopic treatment and urethroplasty] to achieve endoscopic treatment and achieve greater success,” says Justin Chee, MD.
Trial of vibegron yields favorable results for patients with OABOctober 16th 2021
"We believed that the drug would work as well in OAB wet as it did in OAB dry, so we're pleased to see that it was statistically significantly better than placebo at the 12-week point for looking at response to both metrics in both group," says David Staskin, MD.
White paper addresses ethical considerations for older patients with incontinenceOctober 15th 2021
"As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on," says Anne M. Suskind, MD, MS, FACS, FPMRS.
Low bladder contractility linked with deterioration of voiding function post RARPOctober 14th 2021
“Qmax at 1, 3, 6, 9, and 12 months and voiding volume at 3 months were significantly lower in the impaired group than in the preserved group. This suggests that preoperative lower bladder contractility was associated with prolonged deterioration of voiding function,” says Junya Hata, PhD.
Surgeons weigh in on MUS surgery for patients with stress urinary incontinenceOctober 12th 2021
“I think the surgeon voice is an important voice to be heard because there's not a lot of avenues for surgeons to be able to be honest and share all the things they've learned and all the things they've experienced with their patients,” says Una Lee, MD, FPMRS.
Regenerative therapy linked to QOL benefit for patients with SUIOctober 11th 2021
In this interview, Melissa R. Kaufman, MD, PhD, FACS, describes the promise of a regenerative approach to treating recurrent incontinence in women known as autologous muscle derived cells for urinary sphincter repair (AMDC-USR).